arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Lunai Bioworks Inc.

LNAI
$0.15 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
64 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
62
Health
Fair
Bullish
auto_awesome

Analytical Summary

Lunai Bioworks Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 18.7% ↗
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Oct 29, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.05K
↑ +48.3% —
Net Income Profit after all expenses
$-2.01M
↑ +98.4% —
FCF / Share Free cash flow per share
$-0.04
↑ +9.9% —
Long-Term Debt Long-term obligations
$102.71K
↑ +1.3% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
92
Financial Health ↑
16
Cash Quality ↑
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 64 quarters